SYNAGIS Drug Profile

Summary for Tradename: SYNAGIS

High Confidence Patents:	0
Applicants:	1
BLAs:	1
Recent Clinical Trials:	See clinical trials for SYNAGIS

Recent Clinical Trials for SYNAGIS

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
mAbxience S.A	Phase 1
Iqvia Pty Ltd	Phase 2
AstraZeneca	Phase 2

See all SYNAGIS clinical trials

Pharmacology for SYNAGIS

Mechanism of Action	Fusion Protein Inhibitors
Established Pharmacologic Class	Respiratory Syncytial Virus Anti-F Protein Monoclonal Antibody
Chemical Structure	Antibodies, Monoclonal

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for SYNAGIS Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for SYNAGIS Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for SYNAGIS Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Swedish Orphan Biovitrum Ab (publ)	SYNAGIS	palivizumab	For Injection	103770	10,005,833	2035-12-31	Patent claims search
Swedish Orphan Biovitrum Ab (publ)	SYNAGIS	palivizumab	For Injection	103770	10,011,584	2035-05-01	Patent claims search
Swedish Orphan Biovitrum Ab (publ)	SYNAGIS	palivizumab	For Injection	103770	10,035,843	2036-02-12	Patent claims search
Swedish Orphan Biovitrum Ab (publ)	SYNAGIS	palivizumab	For Injection	103770	10,081,671	2035-10-29	Patent claims search

Market Dynamics and Financial Trajectory for SYNAGIS (Palivizumab)

Last updated: March 20, 2026

What is the Current Market Position of SYNAGIS?

SYNAGIS (palivizumab) is a monoclonal antibody indicated for the prevention of severe respiratory syncytial virus (RSV) infections in high-risk infants. It held approximately $1.2 billion in global sales in 2022, with a compound annual growth rate (CAGR) of 4% from 2018 to 2022. The drug's market dominance is driven by its unique role in prophylaxis for preterm infants, children with congenital heart disease, and chronic lung disease.

How Is the Market for RSV Prevention Evolving?

Growing Incidence of RSV

RSV is responsible for 60% of bronchiolitis cases and causes 100,000 hospitalizations annually in the U.S.[1]. The global RSV vaccine market is expanding, projected to reach $4.2 billion by 2030, with a CAGR of 7%. The spike in hospitalizations during recent winters heightened awareness and demand for prophylactic options.

Competition and Pipeline Developments

Despite SYNAGIS's market dominance, it faces competition from emerging long-acting monoclonal antibodies and vaccines:

• Nirsevimab: A long-acting monoclonal antibody with a half-life of 5 months, enabling a single dose for RSV season. Phase 3 trials showed efficacy comparable to SYNAGIS and are expected to expand its market share.

• RSV Vaccines: Several candidates are in late-stage clinical trials for maternal immunization, targeting infants via transplacental antibodies. Their approval could disrupt current prophylaxis strategies.

Regulatory and Policy Impact

In 2023, the U.S. FDA approved updated guidelines recommending expanded prophylaxis to additional high-risk groups. Medicaid and private payer coverage for SYNAGIS remains robust, but reimbursement pressures persist, especially as competitors gain approval.

What Are the Financial Drivers and Challenges?

Revenue Drivers

• Pricing and Reimbursement: In the U.S., SYNAGIS is priced at ~$1,200 per dose, with each patient receiving 5 doses per RSV season, totaling ~$6,000. Insurance coverage remains high, supporting revenue stability.

• Market Penetration: The drug's established safety profile and clinician familiarity sustain high prescription rates in NICUs.

• Expanding Indications: Ongoing research into broader populations, such as late preterm infants, could expand the target market.

Challenges to Revenue Growth

• Patent Expiry: Patent expiration is anticipated around 2025-2027. Biosimilars are in development, which could reduce prices and market share.

• Pricing Pressures: Pricing caps and formulary restrictions in Europe and parts of Asia could limit revenue growth.

• Development of Alternatives: The approval and adoption of long-acting monoclonal antibodies and maternal vaccines may reduce the demand for SYNAGIS.

Financial Outlook

GSK, the manufacturer of SYNAGIS, projects stable sales through 2025, with a gradual decline post-2027 as biosimilars enter the market. Investment in pipeline products, such as nirsevimab, is positioned as a key growth driver to offset potential revenue erosion.

How Are Market Access and Pricing Policies Impacting SYNAGIS?

Pricing and reimbursement policies significantly affect SYNAGIS's market trajectory. The U.S. Centers for Medicare & Medicaid Services (CMS) set reimbursement rates for prophylaxis, influencing hospital prescribing behaviors. In Europe, national health systems impose price controls that have led to negotiated discounts, impacting profit margins.

What Is the Broader Industry Context?

The RSV prophylaxis market is part of the larger pediatric infectious disease therapeutics sector, which is experiencing incremental growth due to increased awareness, improved diagnostics, and evolving preventive technologies. The trend favors long-acting biologics and vaccines, which challenge traditional monthly dosing regimens.

---

Key Data Summary

Metric	2022 Data	Forecast / Comparison
Global SYNAGIS sales	$1.2 billion	4% CAGR (2018-2022)
Major competitors	Nirsevimab, RSV vaccines	Nirsevimab market expected to rival SYNAGIS
Price per dose	~$1,200	Fixed by payer negotiations
Doses per RSV season	5 doses	Market standard
Patent expiry	2025-2027	Biosimilars in development
RSV vaccine market size (2023)	$1.6 billion	Target to reach $4.2 billion by 2030

---

Key Takeaways

• SYNAGIS maintains a leading position in RSV prophylaxis with stable revenues but faces impending patent expiration.
• The emergence of long-acting monoclonal antibodies like nirsevimab and prospective maternal vaccines threaten market share.
• Regulatory updates and payer policies influence sales trajectories, with reimbursement generally supporting current levels.
• Market growth driven by rising RSV cases, but competitive pressures could limit expansion.
• Investment in pipeline innovations is crucial for sustaining long-term revenue streams.

FAQs

1. When will SYNAGIS patents expire?
Patents are expected to expire between 2025 and 2027, after which biosimilars could enter the market.

2. What is the potential impact of nirsevimab on SYNAGIS sales?
Nirsevimab's single-dose regimen and comparable efficacy could reduce SYNAGIS demand, especially if approved widely and adopted in clinical practice.

3. Are there upcoming regulatory changes that might affect SYNAGIS?
Yes, the FDA has recommended expanded prophylaxis coverage, which could increase prescriptions but may also introduce pricing and reimbursement pressures.

4. How does the pricing of SYNAGIS compare globally?
Prices vary; in Europe, negotiated discounts lower costs, whereas in the U.S., the $1,200 per dose rate is typical.

5. What are the prospects for RSV vaccine development?
Multiple maternal vaccine candidates are in late-stage trials, with potential to replace passive immunization in high-risk infants upon approval.

---

References

[1] Centers for Disease Control and Prevention. (2021). Respiratory Syncytial Virus (RSV). CDC.gov.